This report contains detailed information about the company's business finances and management.
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 30.56 | -0.17 -0.55% | 3.38% | 2,671,089 | 25.1M |
aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. PREGNANCY CATEGORY B There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--July 17, 2014-- Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion (administered through electric shock to the chest or with medication) is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively. Traditionally, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward. In some patients, early cardioversion can be performed on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke.
Pfizer's Get Old Campaign Challenges Conventional Attitudes about Aging New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 2013(2) NEW YORK--(BUSINESS WIRE)--July 16, 2014--
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. Primary Care operating segment includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians. In November 2012, the Company acquired NextWave Pharmaceuticals, Inc. On November 30, 2012, the Company completed the sale of its Nutrition business.
| Bid/Size | Ask/Size |
|---|---|
| -- / -- | -- / -- |
| Price Open | Previous Close |
|---|---|
| 30.43 | 30.73 |
| Day High | Day Low |
|---|---|
| 30.64 | 30.30 |
| 52wk High/Date | 52wk Low/Date |
|---|---|
| 32.96 / 3/6/2014 | 27.76 / 8/27/2013 |
| % off 52wk High | % off 52wk Low |
|---|---|
| (7.28)% | 10.09% |
| Beta (5 Yr) | Market Capitalization |
|---|---|
| 0.7 | 194.7B Large Cap |
| Shares Outstanding | Volatility Avg |
|---|---|
| 6.4B | 15.69 |
| EPS(TTM) | P/E Ratio |
|---|---|
| 1.64 | 18.6 |
| Dividend Announcement | Dividend Yield |
|---|---|
| 6/26/2014 | 3.38% |
| Ex-Date | Date of Record |
|---|---|
| 7/30/2014 | 8/1/2014 |
| Payable | Payable Date |
|---|---|
| 0.26 - QRTR | 9/3/2014 |
| Peers | |
|---|---|
PFE Pfizer Inc | 0.33% |
Johnson & Johnson | 11.15% |
Merck & Co., Inc. | 16.56% |
Abbott Laboratories | 11.48% |
Eli Lilly and Co | 24.45% |
PFE Pfizer Inc | 3.40% |
Johnson & Johnson | 2.75% |
Merck & Co., Inc. | 3.02% |
Abbott Laboratories | 2.06% |
Eli Lilly and Co | 3.09% |
PFE Pfizer Inc | -0.55% |
Johnson & Johnson | -0.30% |
Merck & Co., Inc. | -0.59% |
Abbott Laboratories | -0.89% |
Eli Lilly and Co | -0.74% |